



International COVID-19 Blood Cancer Coalition (ICBCC)

PATIENT IMPACT STATEMENT AND RECOMMENDATIONS **Protecting immunocompromised blood cancer patients during the COVID-19 pandemic**

Date of release: 21 February 2022 / last updated: 13 June 2022

A multi-stakeholder coalition consisting of representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients (both acute and chronic), and to recommend solutions and actions to mitigate those risks.

The Problem

The estimated share of those who are immunocompromised (IC) is between two and three percent of the total global population. All are more vulnerable to contracting and suffering poor outcomes with COVID-19. Sadly, during the last two years their circumstances have been neglected to a larger or smaller extent with marked differences across geographical locations, leaving some to call them the "Prisoners of the Pandemic".

Their antibody responses to COVID-19 vaccines and even boosters have been repeatedly proven less predictable and robust when compared to the general population^{i, ii, iii, xxiii, xxiv, xxv, xxviii}. However, there is also evidence that boosters do yield benefits for people living with hematologic malignancies^{xiii, xxvi}.

What is known is that immunocompromised (IC) patients¹ in general, and blood cancer patients in particular, have:

1. Much greater risk from COVID-19 including higher rates of hospitalization, ICU admissions and death^{iv, xviii, xix, xx, xxi, xxii}.
2. Higher rates of breakthrough infections after being fully vaccinated^y.
3. Higher rates of their infection spreading from household contacts.
4. No simple lab test to reliably predict protection post vaccination.
5. Shown in some cases to carry and shed severe acute respiratory syndrome coronavirus 2 (or SARS-CoV-2) for months leading to the risk of introducing potentially dangerous new mutations into the broader population^{vi}.

While ~97% of the adult population has the option of a safe and extremely effective way to prevent severe COVID-19 and can re-engage in the world by getting vaccinated, the vulnerable 2-3%, namely

¹ For the purposes of this statement, we use this definition of immunocompromised: Having a weakened immune system can make you more likely to get severely ill from COVID-19. Many conditions and treatments can cause a person to be immunocompromised or have a weakened immune system. Primary immunodeficiency is caused by genetic defects that can be inherited. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>



the IC patients, continue to be cautioned by local and global health authorities not to rely on vaccines for protection^{vii}.

The definition of who is considered immunocompromised is unclear and absent of precise diagnostic and clinical indicators. One example is those with Chronic Lymphocytic Leukemia (CLL) who have long been recognized as being significantly immunocompromised at all stages of disease, regardless of their treatment status^{viii}. Quoting from a recent study of COVID-19 vaccine response in blood cancer patients: "More than one-third (36%) of patients with CLL, the most common leukemia in U.S. adults, were seronegative after vaccination. Nearly three in ten of them had no cancer therapy in the past two years, showing that the disease itself may impair the B cell function needed to make antibodies to vaccines." ^{ix} Moreover, we know that we cannot rely on any single blood test to determine vulnerability to COVID-19.

As a significant stressor, the COVID-19 pandemic has also resulted in the **deterioration of mental health** in some patient groups^{x, xv, xxvii}, specifically multiple stressing factors of being immunocompromised, being less protected than others, and continuation of shielding from the environment, despite the relaxation of public rules.

Principles

The mantra of "**Get vaccinated, but act as if you are not**" is an appropriate interim solution. However, IC patients should not be expected to remain locked down indefinitely as the rest of the world returns to near normal.

The special vulnerability of those with blood cancers and others needs to be addressed in a proactive way. While needing to be prepared for surprises when dealing with COVID-19, certain principles can inform best practices for the IC community:

1. There is public fatigue with health measures.
2. Public awareness of issues for IC is important.
3. IC blood cancer patients must be included in the priority treatment groups with those considered at high risk and most vulnerable to COVID-19 infection. **Everyone, regardless of their immune status, should be vaccinated.** The active immunity from a vaccine is preferred for those who can rely on it. The more people are vaccinated, including booster vaccine doses, the more the IC are protected.
4. Strategies and actions for IC need to rely on post-exposure antivirals and pre-exposure COVID-19 monoclonal antibodies (CmAbs).
5. **Educating the IC patients that continued masking and social distancing** in high-risk circumstances are essential even if the public rules on masking and social distancing are relaxed. This is especially true in settings where the IC will likely be present such as during public transit and in public buildings.
6. **Safety measures and masking should continue to be maintained in any clinical setting when treating IC patients** even when public rules are being relaxed.

Recommendations



1. **Access to fast response COVID-19 testing for high-risk patients^{xvi}.** Many of the lifesaving therapies must be instituted quickly after diagnosis to be effective. Waiting a week for the results of a PCR test could be a fatal delay. Possible solutions include:
 - a. Special access to home tests for the IC community.
 - b. Testing slots set aside or special testing sites for the IC.
 - c. Systems should be in place at national level to process the IC that test positive to COVID-19 to ensure a quick access to treatment.
2. **Access to Pre-Exposure Prophylaxis or PrEP and Post Exposure Prophylaxis or PEP, and antivirals for high-risk patients.** When vaccination does not provide protection, there must be adequate access to appropriate therapies to prevent and treat infections. A critical claim, it can be achieved by accelerating the production and equitable distribution of antivirals and CmAbs. There are good options but scarce supplies.
3. **Using scientific rigor to best define who is at high risk for COVID-19.** It cannot be based on a single blood value and instead should be informed by the increasing volume of scientific literature on COVID-19 outcomes in several different IC communities. This is especially true for all those with lymphoid malignancies including many lymphomas such as CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma), regardless of whether they are before, during or after treatment.
4. **More research** is needed about blood cancer and IC patients and existing and future antivirals.
5. **Ensuring equitable access to best practices and treatments as well as affordable PPE and COVID-19 tests** regardless of geographic, socio-economic, racial or ethnic considerations.
6. All those who might benefit should be offered additional **vaccine doses^{xii}**. Booster vaccine doses should be offered **especially to the elderly and immunocompromised** based on studies demonstrating their protective benefits
7. **Involvement of the medical institutions in low and middle income countries** in the clinical studies / trials of new anti-COVID-19 medications.
8. **Provision of psychological and psycho-oncological services** specifically to the immunocompromised who need to continue shielding and social distancing despite the relaxation of public rules^{xiv}. Offering the right protective measures complete with a comprehensive strategy to protect the patients from the multiple stressing factors of being immunocompromised, less protected than others, being in lockdown or otherwise shielding from the environment will lead to better physical and mental health outcomes.
9. **Vaccines must be made available globally**, not only in high income countries. Reliable information about vaccines and treatments should be made available and more visible.

Until there is enough antiviral and antibody therapy for all who might benefit, difficult choices will need to be made to ensure equitable access.

Protecting the most vulnerable is not only the right thing to do, but also the smart thing to do. Protecting the immunocompromised where the virus has proven to linger and mutate, protects everyone^{xii}.

COVID-19 management is changing rapidly. While this represents the consensus as to best practices at the time of its publication, new options will require ongoing updates. And so, it is also essential to ramp up research into identifying the factors of neglected care for the broader patient community of IC patients.



Thank you for considering the needs of this large population who have been largely forgotten during the pandemic.

On behalf of the International COVID-19 Blood Cancer Coalition (ICBCC)

Launch date: 21st of February 2022, Last updated: 13th of June 2022

Endorsed by:

Global Patient Organisations:



Nick York, Chair
CLL Advocates Network
(Global)



**Dr Brian Koffman, Executive
Vice President and Chief Medical
Officer**
CLL Society
(USA)



**Lorna Warwick,
Chief Executive Officer**
Lymphoma Coalition
(Global)



**Dennis Costello, Executive
Director**
CML Advocates Network
(Global)



Zack Pemberton-Whiteley, Chair
Acute Leukemia Advocates
Network, ALAN
(Global)



**Sophie Wintrich, Steering
Committee Member**
The MDS Alliance
(Global)



Lord Mendelsohn, Trustee
Follicular Lymphoma Foundation
(global)



Hans Scheurer, President
Myeloma Patients Europe, MPE
(Europe)



**Andreas Charalambous,
President**
European Cancer Organisation



(Europe)



Fernando Piotrowski, Executive Director
Asociación ALMA
(Argentina)



Chris Tanti, CEO
Leukaemia Foundation
(Australia)



Sharon Winton, CEO
Lymphoma Australia
(Australia)



Hyacinth Grimes, Vice President
Lymphoma and Leukemia
Foundation of Barbados
(Barbados)



Elke Stienissen, President
Lymphoma Association Flanders
(Belgium)



Reymond Vles, Chair
CLL Canada
(Canada)



Nadine Prévost, Senior Director
The Leukemia & Lymphoma
Society of Canada
(Canada)



Nury Esperanza Villalba Suárez, Executive Director
Fundación Esperanza Viva
(Colombia)



Silvia Diaz, President
AGALEMO
(Costa Rica)



Dražen Vincek, President
Hrvatska Udruga Leukemija i
Limfomi, HULL



Jana Pelouchova, President
Diagnóza Leukemie
(Czech Republic)



Rita O. Christensen, President
Patient Advocacy Group for



Lymphoma, Leukemia and MDS,
LyLe
(Denmark)

(Croatia)



Pierre Aumont, Trustee
Ensemble Leucémie Lymphomes
Espoir - ELLyE
(France)



Rainer Göbel, Chairman
Deutsche Leukämie- und
Lymphom-Hilfe, DLH
(Germany)



Jan Geissler, Founder
Leukaemie-Online.de
(Germany)



Jan Geissler, Chair
LeukaNET
(Germany)



Kimon Ourountzoglou
Hellenic Group of Patients with CLL
(Greece)



Vandana Gupta, Founder
V Care Foundation
(India)



Michael Rynne, Co-founder
CLL Ireland
(Ireland)



**Rachel Morrogh, Director of
Advocacy & External Affairs**
Irish Cancer Society
(Ireland)



Giora Sharf, Director
Flute of Light - Home of blood
cancer patients in Israel
(Israel)





Lidija Pecova, President
HEMA
(Macedonia)

Mayra Galindo, Director
Mexican Association of the Fight
Against Cancer - AMLCC
(Mexico)

Bahija Gouimi, President
AMAL
(Morocco)



**Krishna Prasad Upadhyaya, Vice
Chairman**
Blood Cancer Society Nepal
(Nepal)



**Marianne van
Maarschalkerweerd, Expert
Patient Advocate**
Hematon
(The Netherlands)



**Emma Barker, Head of Support
Services & Operations**
Leukaemia & Blood Cancer New
Zealand
(New Zealand)



Dr Gillian Corbett, Trustee
CLL Advocates New Zealand,
CLLANZ
(New Zealand)



Oksana Chirun, President
Inter-regional public organization
for patients with hematological
diseases «Most Miloserdiya»
(«Mercy Bridge»)
(Russia)



Maja Kocic, President
Lymphoma Patient Association
LYPA / LIPA
(Serbia)



**Kristina Modic
Executive Director**
Slovenian Lymphoma and
Leukemia Patient Association, L&L
(Slovenia)



**Elena Palma, International
Representative**
AELCLES (Spanish Network for
Leukemia and Blood Disorder)
(Spain)



Lise-lott Eriksson, President
Blodcancerförbundet / The
Swedish Blood Cancer Association
(Sweden)



Dr Jeroen Goede, President
SFK- Stiftung zur Förderung der
Knochenmarktransplantation
(Switzerland)



Rosmarie Pfau, President
Lymphome.ch Patientennetz
Schweiz
(Switzerland)



Gerard Masalago, Chairman
Blood Cancer Foundation
Tanzania
(Tanzania)



**Zack Pemberton-Whiteley, Chief
Executive Officer**
Leukaemia Care
(UK)



**Dallas Pounds, Director of
Services**
Lymphoma Action
(UK)



Marc Auckland, Chair
CLL Support
(UK)




**Helen Rowntree, Director of
Research, Services &
Engagement**
Blood Cancer UK
(UK)



Tom Mallon, Coordinator
Leukaemia & Lymphoma NI
(UK)



**Sophie Wintrich, Chief
Executive/Patient Liaison**
MDS UK Patient Support Group
(UK)



Dr Adrian Warnock, Founder
Blood Cancer Uncensored
(UK / USA / Canada)



Ivan Zelenskyi, Director
Charity Fund of patients "Drop of
Blood"
(Ukraine)



**Gwen Nichols, MD, Chief
Medical Officer**
The Leukemia & Lymphoma
Society
(USA)



Esther Schorr, Co-Founder
Patient Power
(USA)

Clinical community / Medical Societies:



Elizabeth Macintyre, President
European Hematology Association,
EHA
(Europe)



Prof Paolo Ghia, President
European Research Initiative on
CLL, ERIC
(Europe)



Prof Peter Hillmen, Chairperson
International Workshop on Chronic
Lymphocytic Leukemia (iwCLL)
(Global)





Dr Yervand Hakobyan, President
AHA - Armenian Hematology
Association
(Armenia)

**Vanessa O'Shaughnessy,
Director Communications**
Peter MacCallum Cancer Centre
(Australia)

Dr Versha Banerji, Physician
(Canada)



**Prof Alain Delmer & Prof Pierre
Feugier**
CLL Scientific Board
French Innovative Leukemia
Organization
(France)



CERTH
CENTRE FOR
RESEARCH & TECHNOLOGY
HELLAS

**Dr Kostas Stamatopoulos,
Director**
Institute of Applied Biosciences
CERTH - Center for Research and
Technology Hellas
(Greece)

Dr Alina Gerrie, Hematologist
British Columbia
(Canada)



Dr Tamar Tadmor, Physician
The Israeli CLL Study Group
(Israel)



Dr Marco Vignetti, President
GIMEMA
(Italy)



IMSP Institutul Oncologic

Dr Vasile Musteata, Physician
Society of hematologists and
transfusiologists
State University of Medicine and
Pharmacy "N. Testemitanu",
Institute of Oncology
(Moldava)



Dr Renata Walewska, Chair
UK CLL Forum
(UK)



**UNIVERSITY OF
BIRMINGHAM**

Prof Paul Moss, Physician
Chief Investigator of the CLL-
Vaccine Response Study,
Birmingham
(UK)



Prof Adele Fielding, President
British Society for Haematology
(UK)



**Anne Crook, Counsellor /
Psychotherapist, Psycho-
oncology
(UK)**

**Dr Dominic Culligan, Chairman
UK MDS FORUM
(UK)**

Nicole Lamanna, MD
Director CLL Program
Hematologic Malignancies Section
Herbert Irving Comprehensive
Cancer Center
New York-Presbyterian/Columbia
University Medical Center
(USA)

Selected References:

- i. Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., ... Ghia, P. (2021). Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood*, 137(23), 3165–3173. <https://doi.org/10.1182/blood.2021011568>.
- ii. Greenberger, L. M., Saltzman, L. A., Senefeld, J. W., Johnson, P. W., DeGennaro, L. J., & Nichols, G. L. (2021). Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell*, 39(8), 1031–1033. <https://doi.org/10.1016/j.ccell.2021.07.012>.
- iii. Re, D., Seitz-Polski, B., Carles, M., Brglez, V., Graça, D., Benzaken, S., ... Jérôme, B. (2021). Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies. *MedRxiv*, 2021.07.18.21260669. <https://doi.org/10.1101/2021.07.18.21260669>.
- iv. Roeker, L. E., Scarfo, L., Chatzikonstantinou, T., Abrisqueta, P., Eyre, T. A., Cordoba, R., ... Patel, M. (2020). Worldwide Examination of Patients with CLL Hospitalized for COVID-19. *Blood*, 136(Supplement 1), 45–49. <https://doi.org/10.1182/blood-2020-136408>.
- v. Brosh-Nissimov, T., Orenbuch-Harroch, E., Chowers, M., Elbaz, M., Neshet, L., Stein, M., ... Wiener-Well, Y. (2021). BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clinical Microbiology and Infection*, 27(11), 1652–1657. <https://doi.org/10.1016/j.cmi.2021.06.036>.
- vi. Karataş, A., İnkaya, A. Ç., Demiroğlu, H., Aksu, S., Haziye, T., Çınar, O. E., ... Göker, H. (2020). Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. *Transfusion and Apheresis Science*, 59(5), 102871. <https://doi.org/10.1016/j.transci.2020.102871>.
- vii. Interim Public Health Recommendations for Fully Vaccinated People. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Updated Sept. 1, 2021. (CDC) <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html>.
- viii. Sun, C., & Wiestner, A. (2021). Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia? *Hematology/Oncology Clinics of North America*, 35(4), 827–845. <https://doi.org/10.1016/j.hoc.2021.03.010>.
- ix. Study from The Leukemia & Lymphoma Society Shows COVID-19 Vaccine is Safe but 25% Of Blood Cancer Patients Do Not Produce Detectable Antibodies. (Leukemia & Lymphoma Society). July 22, 2021. <https://www.lls.org/news/study-leukemia-lymphoma-society-shows-covid-19-vaccine-safe-25-blood-cancer-patients-do-not>.
- x. Lindoso, L., Astley, C., Queiroz, L. B., Gualano, B., Pereira, R. M. R., Tannuri, U., ... Silva, C. A. (2021). Physical and mental health impacts during COVID-19 quarantine in adolescents with preexisting chronic immunocompromised conditions. *Jornal de Pediatria*. <https://doi.org/10.1016/j.jped.2021.09.002>.



- xi. Al-Rahimi, J. S., Nass, N. M., Hassoubah, S. A., Wazqar, D. Y., & Alamoudi, S. A. (2021). Levels and predictors of fear and health anxiety during the current outbreak of COVID-19 in immunocompromised and chronic disease patients in Saudi Arabia: A cross-sectional correlational study. *PLOS ONE*, 16(4), e0250554. <https://doi.org/10.1371/journal.pone.0250554>.
- xii. Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Alroy-Preis, S., ... Milo, R. (2021). Protection against Covid-19 by BNT162b2 Booster across Age Groups. *New England Journal of Medicine*, 385(26), 2421–2430. <https://doi.org/10.1056/NEJMoa2115926>.
- xiii. <https://www.lls.org/news/largest-study-date-demonstrates-most-blood-cancer-patients-benefit-third-primary-dose-mrna>, last accessed: 08.02.2022
- xiv. Zomerdijk, N., Jongenelis, M., Yuen, E., Turner, J., Huntley, K., Smith, A., ... Short, C. E. (2021). Experiences and needs of people with haematological cancers during the COVID-19 pandemic: A qualitative study. *Psycho-Oncology*, pon.5819. <https://doi.org/10.1002/pon.5819>.
- xv. Zomerdijk, N., Jongenelis, M., Short, C. E., Smith, A., Turner, J., & Huntley, K. (2021). Prevalence and correlates of psychological distress, unmet supportive care needs, and fear of cancer recurrence among haematological cancer patients during the COVID-19 pandemic. *Supportive Care in Cancer*, 29(12), 7755–7764. <https://doi.org/10.1007/s00520-021-06369-5>.
- xvi. <https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/who-is-at-high-risk-from-coronavirus>, last accessed 11.02.2022
- xvii. Veronique Nussenblatt, Allison E Roder, Sanchita Das, Emmie de Wit, Jung-Ho Youn, Stephanie Banakis, Alexandra Mushegian, Christopher Mederos, Wei Wang, Matthew Chung, Lizzette Pérez-Pérez, Tara Palmore, Jennifer N Brudno, James N Kochenderfer, Elodie Ghedin. Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion, *The Journal of Infectious Diseases*, Volume 225, Issue 7, 1 April 2022, Pages 1118–1123, <https://doi.org/10.1093/infdis/jiab622>; last accessed: 02.05.2022
- xviii. Aries, J.A. et al. (2020). Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. *Br J Haematol.*, 190: e64–e67.
- xix. Fox, T.A. et al. (2020). Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. *Br J Haematol.*, 191: 194–206
- xx. Garnett, C. et al. (2021). Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom. *Leuk Lymphoma.*, 62: 469–472.
- xxi. Wood, W.A. et al. (2020). Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. *Blood Adv.*,4: 5966–5975.
- xxii. Vijenthira, A. et al. (2020). Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. *Blood*, 136(25): 2881-2892
- xxiii. Herishanu, Y. et al. (April 16, 2021). Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood*, 2021011568
- xxiv. Benda, M. et al. (August 3, 2021). Serological SARS-Cov-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. *Br J Haematol.*
- xxv. Jurgens, E.M. et al. (2021). Serologic response to mRNA COVID-19 vaccination in lymphoma patients. *AM J Hematol.* 96(11):E410-E413
- xxvi. Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, Dally N, Shvidel L, Ziv-Baran T, Polliack A, Tadmor T, Benjamini O; Israeli CLL Study Group. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. *Blood*. 2022 Feb 3;139(5):678-685. doi: 10.1182/blood.2021014085. PMID: 34861036; PMCID: PMC8648353.
- xxvii. Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020). The psychological impact of quarantine and how to reduce it: rapid review of the evidence. In *The Lancet* (Vol. 395, Issue 10227, pp. 912–920). Elsevier BV. [https://doi.org/10.1016/s0140-6736\(20\)30460-8](https://doi.org/10.1016/s0140-6736(20)30460-8)
- xxviii. Yair Herishanu, Irit Avivi, Shai Levi, Gabi Shefer, Yotam Bronstein, Miguel Morales Moshiahvili, Tomer Ziv, Lydia Scarfò, Chava Perry, Paolo Ghia; Six-month antibody persistence after BNT162b2 mRNA



COVID-19 vaccination in patients with chronic lymphocytic leukemia. *Blood Adv* 2022; 6 (1): 148–151. doi: <https://doi.org/10.1182/bloodadvances.2021005998>

Further Reading:

- <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>
- <https://www.hematology.org/covid-19/covid-19-and-cll>
- <https://www.hematology.org/covid-19/covid-19-and-myelodysplastic-syndromes>
- <https://ehaweb.org/covid-19/covid-19-recommendations/recommendations-for-specific-hematologic-malignancies>
- Francesco Forconi, Paul Moss; Perturbation of the normal immune system in patients with CLL. *Blood* 2015; 126 (5): 573–581. doi: <https://doi.org/10.1182/blood-2015-03-567388>
- Nassef Kadry Naguib Roufaiel M, Wells JW, Steptoe RJ. Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. *Front Immunol.* 2015;6:258. Published 2015 Jun 2. doi:10.3389/fimmu.2015.00258
- Shree T, Li Q, Glaser SL, Brunson A, Maecker HT, Haile RW, Levy R, Keegan THM. Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. *J Clin Oncol.* 2020 May 20;38(15):1664-1675. doi: 10.1200/JCO.19.01937. Epub 2020 Feb 21. PMID: 32083991; PMCID: PMC7238489.
- Musteata V. Covid-19 in Patients with Chronic Myeloid Leukemia: Management Challenges and Outcomes. *Archives of the Balkan Medical Union.* 2021. vol. 56, no. 4, pp. 455-460